U.S. Solid Tumor Testing Market Advances as Thermo Fisher Scientific Expands Precision Oncology, with Global Market Rising from USD 32.9 billion in 2026 to USD 65.9 billion by 2036 at a 7.2% CAGR

ROCKVILLE, MARYLAND , August 24, 2026 — The global solid tumor testing market reached a valuation of USD 30.7 billion in 2025. Demand is projected to expand from USD 32.9 billion in 2026 to USD 65.9 billion by 2036, recording a compound annual growth rate (CAGR) of 7.2% over the ten-year forecast period.

According to market data published by Fact.MR, the industry represents an absolute expansion opportunity of USD 33.0 billion between 2026 and 2036.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15842

Executive Summary & Key Findings

Solid tumor testing products and services are utilized by healthcare providers to identify molecular and genomic signals within solid tumors to guide diagnosis, therapy selection, and disease monitoring.

• Primary Market Driver: The necessity for genetic testing workflows that directly connect tumor types and specific biomarker results with actionable treatment decisions.
• Core Product Dominance: Genetic testing products lead the market share, driven by widespread adoption of tumor genotyping across oncology centers.
• Dominant Application: Breast cancer testing represents the largest application segment due to routine receptor and HER2 mutation profiling.
• Leading Technology: Next-Generation Sequencing (NGS) controls the highest technology share owing to its ability to consolidate multi-biomarker evaluation into a single workflow.

Market Growth Drivers

Fact.MR identifies several primary quantitative growth factors accelerating market expansion from 2026 to 2036:

1.     Genetic Testing Specification Pull (+1.8% CAGR Impact): Short-term adoption (<= 2 years) driven by clinician demand for actionable biomarker reports, particularly in South Korea and the USA.

2.     Breast Cancer Clinical Workflow Integration (+1.5% CAGR Impact): Short-term growth (<= 2 years) across the USA, Australia, and Canada, where HER2 and hormone receptor testing remain mandatory pathology requirements.

3.     Hospital Oncology Menu Expansion (+1.2% CAGR Impact): Medium-term adoption (2–4 years) in South Korea and Germany as healthcare systems integrate molecular diagnostic platforms directly into hospital tumor boards.

4.     Direct Service and Validation Support (+0.9% CAGR Impact): Medium-term expansion (2–4 years) across Canada, the UK, and Japan, where institutions favor suppliers offering on-site technical validation.

5.     NGS Panel Consolidation (+0.8% CAGR Impact): Long-term growth (>= 4 years) across hospital and reference laboratory networks seeking to replace single-gene assays with comprehensive multi-gene panels.

Detailed Segment Analysis

Segment Breakdown by Product Type

• Genetic Testing: Projected to hold a 38.1% market share in 2026. Clinicians prioritize genetic testing because tumor genotyping links specific mutations directly to targeted therapeutic options.
• Other Product Segments: Cancer tumor profiling and secondary assay products maintain substantial volume in narrow diagnostic protocols.

Segment Breakdown by Technology

• Next-Generation Sequencing (NGS): Expected to account for 39.5% of total market share in 2026. NGS allows multi-biomarker analysis from limited tissue specimens in a single run.
• PCR & DNA Diagnostics: Continue to serve focused diagnostic requirements where limited panel choices align with tighter reimbursement limits.

Segment Breakdown by Application

• Breast Cancer: Anticipated to capture 27.8% market share in 2026. Routine pathology reviews mandate HER2 and hormone receptor profiling to establish therapeutic sequencing.
• Lung Cancer Diagnostics: Generates significant secondary volume due to expanding targeted therapy drug labels requiring molecular proof.

Segment Breakdown by End User & Distribution Channel

• Hospitals (End User): Estimated to hold a 30.6% share in 2026, functioning as the main point of clinical decision-making and multidisciplinary tumor board evaluations.
• Direct Sales (Distribution Channel): Forecast to account for 30.0% market share in 2026, as clinical laboratories require direct vendor involvement for equipment installation, software updates, and regulatory validation.

Country-Level Growth Comparison

The solid tumor testing market exhibits varying growth rates across key international geographies based on local healthcare infrastructure, reimbursement policies, and testing accessibility.

Note on Source Inconsistency: The source report text explicitly describes South Korea as "leading" regional growth, yet lists its numerical CAGR at 5.8%, which is lower than the numerical CAGRs published for the USA (9.4%), Japan (8.6%), Germany (7.9%), the UK (7.2%), and Canada (6.5%).

Competitive Landscape & Recent Developments

Key Market Players

The global solid tumor testing ecosystem is led by major international diagnostic and biotechnology corporations, including:

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN N.V.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Guardant Health, Inc.
• Foundation Medicine, Inc.

Regulatory Approvals & Clinical Milestones

• U.S. FDA Approval (P230011): Illumina, Inc. received FDA approval for the TruSight Oncology Comprehensive assay.
• FDA Therapeutic Drug Approval (October 10, 2024): The U.S. FDA approved inavolisib in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, reinforcing demand for companion biomarker testing.
• NHS England ctDNA Program (April 7, 2026): NHS England initiated formal implementation of circulating tumor DNA (ctDNA) liquid biopsy testing across national healthcare networks for disease monitoring and therapy selection.

Market Restraints & Growth Bottlenecks

1.     Reimbursement & Coverage Review (-1.1% CAGR Impact): Short-term restriction (<= 2 years) where payor coverage uncertainty in the USA, Germany, and the UK delays multi-gene panel adoption.

2.     Specimen Quality & Tumor Fraction Limits (-0.9% CAGR Impact): Short-term technical limit (<= 2 years) caused by low tissue volume or low tumor fraction requiring repeat biopsy procedures.

3.     Validation & Reporting Burden (-0.7% CAGR Impact): Medium-term constraint (2–4 years) requiring complex regulatory and clinical compliance documentation in South Korea, Australia, and Canada.

4.     Fragmented Ordering Pathways (-0.5% CAGR Impact): Long-term operational friction (>= 4 years) within smaller regional hospital networks lacking unified diagnostic protocols.

Buyer Decision Guide: How to Choose Solid Tumor Testing Solutions

Procurement officers, pathology directors, and R&D teams evaluating solid tumor testing vendors should assess solutions using six criteria:

1.     Assay Actionability: Verify that panel targets directly correlate with current regulatory drug labels and national clinical guidelines.

2.     Reimbursement Compliance: Ensure the assay format carries designated billing codes and established payor coverage in target regional markets.

3.     Sample Efficiency: Prioritize NGS panels and PCR assays that require low minimal tumor tissue input to mitigate sample rejection rates.

4.     Vendor Validation Support: Select providers offering direct sales, setup support, and staff training to accelerate clinical laboratory onboarding.

5.     Software & Reporting Integration: Confirm that the platform delivers standardized, clinical-grade reports compatible with hospital Electronic Health Records (EHR) and tumor board workflows.

6.     Turnaround Consistency: Confirm that batching requirements and operational run times meet institutional turnaround targets for therapeutic initiation.

Unlock Actionable Insights from the Complete Report: https://www.factmr.com/report/solid-tumor-testing-market

Report Scope & Availability

• Report Code: FACT15842MR
• Publication Date: August 3, 2026
• Page Count: 170 Pages
• Coverage: Product Type, Application, End User, Distribution Channel, Technology, and Regional Forecasts (2026–2036).

Explore More Related Studies Published by Fact.MR Research

Acinetobacter Pneumonia Therapeutics Market- https://www.factmr.com/report/acinetobacter-pneumonia-therapeutics-market

AI Drug Repurposing Market- https://www.factmr.com/report/ai-drug-repurposing-market

Drug Reference Apps Market- https://www.factmr.com/report/drug-reference-apps-market

Erythropoietin (EPO) Drugs Market- https://www.factmr.com/report/erythropoietin-epo-drugs-market

Solid Tumor Testing Market- https://www.factmr.com/report/solid-tumor-testing-market

Veterinary CRO CDMO Market- https://www.factmr.com/report/veterinary-cro-cdmo-market

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

 - Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com